Myeloproliferative Disorder Clinical Trial
Official title:
Aprepitant Versus Hydroxyzine in Association With Cytoreductive Treatments for Patients With Myeloproliferative Neoplasia Suffering From Persistent Aquagenic Pruritus.
Phase 3, randomized prospective study, double blind-double placebo, testing oral therapies APREPITANT versus HYDROXYZINE in patients followed for myeloproliferative neoplasms and suffering of persistent aquagenic pruritus.
Identification of patients with myeloproliferative neoplasms and aquagenic pruritus. Evaluation of the intensity of the aquagenic pruritus. Patients with value >5/10 on the VAS (Visual Analogue Scale ) are proposed to participate to the protocole. Randomization between the two treatments. Duration of the treatment : 14 days. Regular evaluation of efficacity of the drugs (questionnaires). Evaluations will stop 2 months after the last intake. Blood samples will be collected before and after the intakes to study cytokine and neuropeptide levels. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT06246006 -
Functional Characterization of Thrombopoietin/cMPL Receptor Mutations in Myeloproliferative Neoplasia
|
||
| Completed |
NCT03907436 -
The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase
|
N/A | |
| Completed |
NCT03734601 -
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
|
Phase 2 | |
| Completed |
NCT00683046 -
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
|
Phase 2 | |
| Completed |
NCT03149055 -
Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)
|
Phase 2 | |
| Completed |
NCT01866839 -
Preventing Stem Cell Transplant Complications With a Blood Separator Machine
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05884333 -
Cord Blood Transplant in Adults With Blood Cancers
|
Phase 2 | |
| Completed |
NCT00588666 -
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT03480360 -
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
|
Phase 3 | |
| Completed |
NCT00539695 -
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
|
Phase 2 | |
| Recruiting |
NCT03869476 -
Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.
|
N/A | |
| Completed |
NCT00175838 -
Primary Thrombocythaemia 1 Trial
|
N/A | |
| Completed |
NCT03688490 -
Clinical Characteristics of Aquagenic Pruritus in Patients With Myeloproliferative Neoplasms
|
||
| Active, not recruiting |
NCT03434730 -
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
|
Phase 2 | |
| Recruiting |
NCT03852407 -
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
|
Phase 2 | |
| Completed |
NCT01499147 -
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
|
N/A | |
| Completed |
NCT00533923 -
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
|
Phase 2 | |
| Active, not recruiting |
NCT04473911 -
Haplo Peripheral Blood Sct In GVHD Prevention
|
Phase 1 | |
| Completed |
NCT00909467 -
Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases
|
N/A | |
| Completed |
NCT00687414 -
Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders
|